{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling, initiating downstream antitumor immunity.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "2. Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "Evidence is based on preclinical murine models and may not fully translate to humans."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination broadens the tumor immunopeptidome, increasing the fraction of tumor proteins presented on MHC molecules.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "The magnitude of expansion is measured in murine tumors and may differ in human cancers."
    },
    {
      "claim_id": "C03",
      "claim": "PD‑L1 expression in tumor tissue increases after mRNA vaccination, enhancing the targetability of checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "PD‑L1 up‑regulation may reflect an adaptive resistance mechanism rather than a purely beneficial effect."
    },
    {
      "claim_id": "C04",
      "claim": "Combining intratumoral mRNA vaccination with anti‑PD‑L1 therapy improves tumor control in mice and is associated with improved survival in a retrospective human cohort.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "Human evidence is retrospective, non‑randomized, and subject to confounding factors."
    }
  ]
}